Clinical trials: Neuroectodermal Tumors, Primitive
Neuroblastoma
Racotumomab in Patients With High-risk Neuroblastoma
This clinical trial will be carried out in children diagnosed with high-risk neuroblastoma that have achieved a complete or very good partial response after standard therapy.
- Trial name
- NCT02998983
- Testing
- Racotumomab
- Where
- 2 sites in Argentina
- Volunteers
- 39 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Neuroblastoma, GD2 Antibody (Naxitamab)
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients.
- Trial name
- NCT06574698
- Testing
- Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00005576
- Testing
- monoclonal antibody Ch14.18, isotretinoin, aldesleukin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Medulloblastoma
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
This phase I trial is studying the side effects and best dose of GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment.
- Trial name
- NCT00822458
- Testing
- vismodegib, laboratory biomarker analysis, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006258
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 3 sites in United States, Canada
- Sponsor
- Children's Hospital Los Angeles
Recurrent Neuroblastoma, Neuroblastoma
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
Currently there is no known effective treatment for recurrent or resistant neuroblastoma. Fenretinide is an anticancer agent that may work differently than standard chemotherapy.
- Trial name
- SPOC2013-001 (NCT02163356)
- Testing
- Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- South Plains Oncology Consortium
Recurrent Solid Tumor, Recurrent Ewing Sarcoma
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away).
- Conditions
- Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor
- Trial name
- NCT04901702
- Testing
- Onivyde, Talazoparib, Temozolomide
- Where
- 10 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- St. Jude Children's Research Hospital
Brain and Central Nervous System Tumors
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00014573
- Testing
- aldesleukin, autologous tumor cell vaccine, filgrastim
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Neuroblastoma
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the…
- Trial name
- NCT02573896
- Testing
- Dinutuximab, NK Cells, Lenalidomide
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Relapsed Neuroblastoma
Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma
HITC001 is a single institution study to evaluate the efficacy of using a standardized protocol of surgery and radiation for patients with brain metastases in relapsed neuroblastoma.
- Trial name
- NCT03406273
- Testing
- Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS)
- Where
- United States
- Sponsor
- Giselle Sholler
Neuroblastoma
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00025597
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 11 sites in Austria, Belgium and 9 more
- Sponsor
- European Infant Neuroblastoma Study Group - 1999
Neuroblastoma
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
The survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor.
- Trial name
- NCT05027386
- Testing
- Apatinib, Irinotecan, Temozolomide
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Sun Yat-sen University
Relapsed Neuroblastoma
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Neuroblastoma is one of the most common solid childhood tumours, and a major cause of cancer-related death in children. More than 1200 children/young adults a year are diagnosed in USA and Europe.
- Trial name
- BEACON2 (NCT07334301)
- Testing
- Bevacizumab, Dinutuximab beta, Irinotecan (drug)
- Where
- 23 sites in Australia, Austria and 3 more
- Volunteers
- 160 people
- Sponsor
- University of Birmingham
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Neuroblastoma
Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL
The patient's have neuroblastoma that has come back, or not gone away. The cancer is harder to treat now. The investigators would like the patient's to be in this research study to determine the safety and dosage of special cells…
- Trial name
- CYCHEALL (NCT01713439)
- Testing
- Injection of allogeneic neuroblastoma cells
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Baylor College of Medicine
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Glioma, Medulloblastoma
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.
- Trial name
- NCT00404495
- Testing
- Irinotecan, Temozolomide
- Where
- 29 sites in Australia, Belgium and 6 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
Diffuse Astrocytoma, Anaplastic Astrocytoma
Pediatric Long-Term Follow-up and Rollover Study
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT03975829
- Testing
- dabrafenib, trametinib
- Where
- 54 sites in United States, Argentina and 17 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Oligodendroglioma
Natural History of Patients With Brain and Spinal Cord Tumors
This study offers evaluation of patients with brain and spinal cord tumors. Its purpose is threefold: 1) to allow physicians in NIH s Neuro-Oncology Branch to increase their knowledge of the course of central nervous system…
- Conditions
- Astrocytoma, Oligodendroglioma, Glioblastoma, Glioma
- Trial name
- NCT00009035
- Where
- United States
- Volunteers
- 3,050 people
- Sponsor
- National Cancer Institute (NCI)